SelectQuote (SLQT) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
16 Dec, 2025Opening remarks and agenda
Meeting called to order at 9:00 A.M. Central Time on November 11, 2025, with Board members, management, and auditors present.
Inspector of Elections and agenda/rules of conduct introduced; only questions relevant to the three proposals considered.
Notice of meeting and proxy materials distributed to all stockholders of record as of September 23, 2025.
Quorum confirmed, allowing the meeting to proceed.
Shareholder proposals
Three proposals presented: election of two Class III Directors, ratification of Deloitte & Touche as auditors, and advisory vote on executive compensation.
Board recommended approval of all three proposals.
Overview of voting outcomes
Both director nominees, Donald L. Hawks III and Denise L. Devine, elected to serve until the 2028 Annual Meeting.
Deloitte & Touche ratified as independent auditors for the fiscal year ending June 30, 2026.
Executive compensation approved on a non-binding advisory basis by majority vote.
Latest events from SelectQuote
- Revenue up 12% to $537.1M, net income $69.3M, and guidance cut by $40M amid external headwinds.SLQT
Q2 20265 Feb 2026 - FY2024 revenue and EBITDA beat guidance; 2025 growth limited by capital, but outlook strong.SLQT
Q4 202420 Jan 2026 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 202517 Jan 2026 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 202523 Dec 2025 - Board recommends approval of all 2025 meeting proposals, emphasizing performance and governance.SLQT
Proxy Filing1 Dec 2025 - Board recommends approval of all proposals, highlighting governance and pay-for-performance.SLQT
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.SLQT
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.SLQT
Proxy Filing1 Dec 2025 - Q3 FY2025 revenue up 8% to $408.2M; SelectRx and Life growth offset Senior declines.SLQT
Q3 202526 Nov 2025